| REGISTERED NUMBER: 06563486 (England and Wales) |
| PARTNERING HEALTH LIMITED |
| GROUP STRATEGIC REPORT, REPORT OF THE DIRECTORS AND |
| CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| REGISTERED NUMBER: 06563486 (England and Wales) |
| PARTNERING HEALTH LIMITED |
| GROUP STRATEGIC REPORT, REPORT OF THE DIRECTORS AND |
| CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| CONTENTS OF THE CONSOLIDATED FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| Page |
| Company Information | 1 |
| Group Strategic Report | 2 |
| Report of the Directors | 4 |
| Report of the Independent Auditors | 7 |
| Consolidated Income Statement | 10 |
| Consolidated Other Comprehensive Income | 11 |
| Consolidated Balance Sheet | 12 |
| Company Balance Sheet | 13 |
| Consolidated Statement of Changes in Equity | 14 |
| Company Statement of Changes in Equity | 15 |
| Consolidated Cash Flow Statement | 16 |
| Notes to the Consolidated Cash Flow Statement | 17 |
| Notes to the Consolidated Financial Statements | 18 |
| PARTNERING HEALTH LIMITED |
| COMPANY INFORMATION |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| DIRECTORS: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| AUDITORS: |
| Statutory Auditors |
| Chartered Accountants |
| Fryern House |
| 125 Winchester Road |
| Chandlers Ford |
| Hampshire |
| SO53 2DR |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| GROUP STRATEGIC REPORT |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| The directors present their strategic report of the company and the group for the year ended 30 September 2024. |
| REVIEW OF BUSINESS |
| The year ending September 2024 presented both challenges and opportunities for the Group, the challenges being linked to a downturn in the insourcing market, predominantly due to a changing political landscape and less certainty around NHS budgets across all territories. The opportunities came following the work we did in the prior year to create a growth platform in our Healthcare Division, leading us to experience significant revenue, EBITDA and geographical expansion from this part of the business. |
| Our plans to move from being a regional provider to a nationally recognised healthcare company are now bearing real fruit and we continue to grow our footprint across all service lines across the UK. We can now confidently say we have achieved this strategic objective. |
| We have maintained and enhanced the quality of care which we provide and continue to be regarded by the Care Quality Commission (CQC) as a 'dynamic organisation' with 'strong governance and open culture'. We have obtained a rating of 'Outstanding' for one of our services, the first to be inspected under the new assessment regime and the first time our highly invested clinical quality and governance model has been assessed by the CQC. |
| This year was made achievable due to the hard work and dedication of hundreds of hardworking and dedicated people, working tirelessly across a range of projects and services while relying upon everybody's strength and resolve. |
| PRINCIPAL RISKS AND UNCERTAINTIES |
| Based on the Group's activities operating as a healthcare provider in the UK, we recognise the significance of identifying and addressing principal risks and uncertainties inherent in our operations. Our strategic approach to risk management encompasses both financial and non-financial aspects, ensuring resilience and sustainability in an ever-evolving healthcare landscape. |
| Regulatory Compliance and Policy Changes |
| One of the primary risks we face relates to compliance with regulatory requirements and adapting to changes in healthcare policies. The healthcare sector in the UK is subject to frequent regulatory updates and policy reforms which may impact our operations, reimbursement rates and service delivery standards. Failure to comply with regulatory standards or anticipate policy changes could lead to legal ramifications, reputational damage and operational disruptions. |
| Clinical Governance and Patient Safety |
| Ensuring the highest standards of clinical governance and patient safety is fundamental to our mission. However, clinical risks such as medical errors, infection control, and adverse patient outcomes pose significant challenges. Maintaining robust quality assurance processes, investing in staff training and development, and fostering a culture of continuous improvement are essential in mitigating these risks and safeguarding patient welfare. |
| Information Security and Data Privacy |
| With the increasing digitisation of healthcare services, safeguarding sensitive patient information and maintaining data privacy are paramount. Cybersecurity threats, data breaches and regulatory non-compliance pose significant risks to our operations and reputation. Implementing robust information security protocols, conducting regular audits and staying abreast of data protection regulations are essential in mitigating these risks and preserving patient trust. |
| Financial Sustainability and Funding Pressures |
| Financial sustainability is a key concern for healthcare providers amid rising costs, budget constraints and funding pressures. Fluctuations in government funding, changes in reimbursement mechanisms and shifts in patient demographics can impact our revenue streams and cost base significantly. Adopting prudent financial management practices, diversifying revenue sources and exploring cost-saving initiatives are essential in mitigating financial risks and ensuring long-term sustainability. |
| Navigating the complex landscape of risks and uncertainties in the healthcare sector requires a proactive and integrated approach. By identifying, assessing and effectively managing these principal risks, we can safeguard our operations, enhance patient outcomes and position ourselves for long-term success in the UK healthcare market. |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| GROUP STRATEGIC REPORT |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| KEY PERFORMANCE INDICATORS |
| Our key financial performance indicators for the Group are shown below: |
| Year to 30 September | 2024 | 2023 |
| £'000 | £'000 |
| Turnover | 31,676 | 42,372 |
| Profit before tax | 427 | 589 |
| EBITDA | 1,914 | 3,052 |
| ON BEHALF OF THE BOARD: |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| REPORT OF THE DIRECTORS |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| The directors present their report with the financial statements of the company and the group for the year ended 30 September 2024. |
| DIVIDENDS |
| No dividends will be distributed for the year ended 30 September 2024. |
| RESEARCH AND DEVELOPMENT |
| We maintain that innovation is at the core of what we do, and while in previous years the Group's focus on research and development has focused on the development of technical solutions linked to monitoring health and wellbeing, this year we have focused on knitting together established technologies to support efficient and effective healthcare service delivery, across our services lines. We completed development and deployed our bespoke insourcing management system 'PRISM', which has increased operational, compliance and financial effectiveness. |
| EVENTS SINCE THE END OF THE YEAR |
| Information relating to events since the end of the year is given in the notes to the financial statements. |
| DIRECTORS |
| The directors shown below have held office during the whole of the period from 1 October 2023 to the date of this report. |
| FINANCIAL INSTRUMENTS RISKS |
| The Group's operations expose it to a variety of financial risks that include the effects of credit risk, liquidity risk and interest rate risk. The Group constantly reviews financial performance by monitoring levels of debt finance and related finance costs. |
| The Group's principal financial instruments comprise trade debtors, trade creditors, bank balances, loan notes, other loans and hire purchase agreements. The risks applicable to the financial instruments are managed by the Group. |
| Liquidity risk is managed by the close control of cash balances, debtors and creditors. Trade debtors are managed in respect of credit and cashflow risk concerning the credit offered to customers and regular monitoring of both amounts outstanding and credit limits. |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| REPORT OF THE DIRECTORS |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| FUTURE DEVELOPMENTS |
| 2024 has like years before, been founded on our vision and values, which we took the opportunity to refresh along with our expanded team of people, across our divisions, as planned. This led to the creation of a new set of values which were shared across all parts of the organisation; and are: |
| o Truly Care |
| o Team First |
| o Pioneering Innovation |
| o Caring, Accountability, Respect, Efficiency, Teamwork & Fun |
| Our Vision remains to be an innovative healthcare provider, respected for providing a range of the highest quality care solutions. |
| Our Mission is to enable people to remain well, or to receive the best possible health and social care via the provision of high-quality healthcare services. |
| Furthermore, we continue to forge strong partnerships with healthcare providers and commissioners. |
| Our Group continues to be a well-respected provider of healthcare, and having further established our expanded footprint this year, we continue to grow our profile and offer our services across the British Isles, ensuring our customers, service users and regulators remain satisfied that we are the best solution for their needs and will do so by not only living our values, but building upon the core pillars of our success which are: |
| 1. Our People |
| 2. Our Patients |
| 3. Our Performance |
| Our customers and regulators continue to support our business and operations and it is through that support we will continue to strive to be the best we can be, to develop on their behalf and innovate for our combined future. |
| The Directors remain confident in the Group's financial position moving into 2024/25. |
| EMPLOYMENT OF DISABLED PERSONS |
| The Group are committed to developing healthcare services which are personal, fair and diverse. We are keen to ensure that our services make a difference to individual lives and to ensure that the services we provide do so inclusively. We are committed to ensuring that our approach to our employees and potential employees is the same as our approach to our service users being open, honest and transparent, focused and based on our values. |
| The Group recognises that unfair discrimination of any form and victimisation is unacceptable and unlawful. It is in the interests of the organisation and its employees to utilise the skills of the total workforce. The Group does ensure that no employee, worker, contractor or job applicant receives less favourable facilities or treatment (either directly or indirectly) in recruitment, employment or engagement on grounds of age, disability, gender/gender reassignment, marriage/civil partnership, pregnancy/maternity, race, religion or belief, sex, or sexual orientation. |
| The Group is committed to improving access to our premises and services by removing physical and other barriers experienced by our service users, this includes digital access. |
| EMPLOYEE ENGAGEMENT STATEMENT |
| Our people are at the heart of our business. They play an integral role in fulfilling our commitment to our patients. We have approximately 450 employees working throughout the UK, and Guernsey. This is complemented with a host of self-employed, bank and contract workers, reaching as far as 2,000 specialist healthcare professionals. |
| Our HR Strategy is designed to support the future growth of the organisation and maintain stability within the workforce. We will have appropriately trained and experienced employees whilst recognising and developing our high performers. We will be an employer of choice through listening to and acting upon employee feedback, and appropriately rewarding and recognising our employees for demonstrating behaviours in accordance with our core. Our attraction strategies and infrastructure support and promote a diverse and inclusive workforce. |
| Investment in learning and development is considered according to the job role, discussion with line managers on career growth and return on investment to the organisation. We utilise the apprenticeship levy within England and have close partnerships with local providers. |
| THIRD PARTY INDEMNITIES |
| Qualifying third party indemnity provisions for the benefit of the directors were in force during the year under review and remain in force as at the date of approval of the financial statements. |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| REPORT OF THE DIRECTORS |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| STATEMENT OF DIRECTORS' RESPONSIBILITIES |
| The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations. |
| Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to: |
| - | select suitable accounting policies and then apply them consistently; |
| - | make judgements and accounting estimates that are reasonable and prudent; |
| - | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. |
| The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. |
| STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS |
| So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the group's auditors are aware of that information. |
| AUDITORS |
| The auditors, Rothmans Audit LLP, will be proposed for re-appointment at the forthcoming Annual General Meeting. |
| ON BEHALF OF THE BOARD: |
| REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
| PARTNERING HEALTH LIMITED |
| Opinion |
| We have audited the financial statements of Partnering Health Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 30 September 2024 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Consolidated Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice). |
| In our opinion the financial statements: |
| - | give a true and fair view of the state of the group's and of the parent company affairs as at 30 September 2024 and of the group's profit for the year then ended; |
| - | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and |
| - | have been prepared in accordance with the requirements of the Companies Act 2006. |
| Basis for opinion |
| We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. |
| Conclusions relating to going concern |
| In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. |
| Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. |
| Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. |
| Other information |
| The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon. |
| Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. |
| In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. |
| Opinions on other matters prescribed by the Companies Act 2006 |
| In our opinion, based on the work undertaken in the course of the audit: |
| - | the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and |
| - | the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements. |
| REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
| PARTNERING HEALTH LIMITED |
| Matters on which we are required to report by exception |
| In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors. |
| We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: |
| - | adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or |
| - | the parent company financial statements are not in agreement with the accounting records and returns; or |
| - | certain disclosures of directors' remuneration specified by law are not made; or |
| - | we have not received all the information and explanations we require for our audit. |
| Responsibilities of directors |
| As explained more fully in the Statement of Directors' Responsibilities set out on page six, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. |
| In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so. |
| Auditors' responsibilities for the audit of the financial statements |
| Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. |
| Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: |
| We obtained an understanding of the legal and regulatory framework that the Group operates in, focusing on those laws and regulations that had a direct effect on the Group's Financial Statements or that had a fundamental effect of the operations of the Group. The key laws and regulations we considered in this context included the UK Companies Act and the Care Quality Commission (CQC) regulations. |
| Discussions were held within the engagement team regarding how and where fraud might occur in the Group Financial Statements and any potential indicators of fraud. As part of this discussion, we identified potential risk areas such as the completeness of revenue. Audit procedures were designed to ensure all of the risks were addressed. |
| In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to: |
| - enquiring of management as to actual and potential litigation and claims; and |
| - reviewing any correspondence with regulators and the Group's legal advisors. |
| - reviewing reports from CQC inspections and action plans. |
| To address the risk of fraud through management bias and override of controls, we; |
| - performed analytical procedures to identify any unusual or unexpected relationships; |
| - tested journal entries to identify unusual transactions and bias. |
| There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the director and other management and the inspection of regulatory and legal correspondence, if any. |
| Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion. |
| A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors. |
| REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
| PARTNERING HEALTH LIMITED |
| Use of our report |
| This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed. |
| for and on behalf of |
| Statutory Auditors |
| Chartered Accountants |
| Fryern House |
| 125 Winchester Road |
| Chandlers Ford |
| Hampshire |
| SO53 2DR |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| CONSOLIDATED |
| INCOME STATEMENT |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 2024 | 2023 |
| Notes | £'000 | £'000 | £'000 |
| TURNOVER | 3 | 31,676 | 42,372 |
| Cost of sales | 18,976 | 27,339 |
| GROSS PROFIT | 12,700 | 15,033 |
| Administrative expenses | 12,307 | 14,301 |
| 393 | 732 |
| Other operating income | - | 26 |
| OPERATING PROFIT | 5 | 393 | 758 |
| Interest receivable and similar income | 33 | 10 |
| Other finance income | 19 | 24 | 18 |
| 57 | 28 |
| 450 | 786 |
| Interest payable and similar expenses | 6 | 23 | 197 |
| PROFIT BEFORE TAXATION | 427 | 589 |
| Tax on profit | 7 | 92 | (135 | ) |
| PROFIT FOR THE FINANCIAL YEAR |
| Profit attributable to: |
| Owners of the parent | 335 | 724 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| CONSOLIDATED |
| OTHER COMPREHENSIVE INCOME |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 2024 | 2023 |
| Notes | £'000 | £'000 |
| PROFIT FOR THE YEAR | 335 | 724 |
| OTHER COMPREHENSIVE INCOME |
| Actuarial gains/(losses) | 97 | (49 | ) |
| Income tax relating to other comprehensive income |
(52 |
) |
(32 |
) |
| OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF INCOME TAX |
45 |
(81 |
) |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR |
380 |
643 |
| Total comprehensive income attributable to: |
| Owners of the parent | 380 | 643 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| CONSOLIDATED BALANCE SHEET |
| 30 SEPTEMBER 2024 |
| 2024 | 2023 |
| Notes | £'000 | £'000 | £'000 |
| FIXED ASSETS |
| Intangible assets | 9 | 9,040 | 9,946 |
| Tangible assets | 10 | 407 | 392 |
| Investments | 11 | - | - |
| 9,447 | 10,338 |
| CURRENT ASSETS |
| Stocks | 12 | 106 | 110 |
| Debtors | 13 | 6,255 | 6,538 |
| Cash at bank | 771 | 1,813 |
| 7,132 | 8,461 |
| CREDITORS |
| Amounts falling due within one year | 14 | 12,929 | 15,461 |
| NET CURRENT LIABILITIES | (5,797 | ) | (7,000 | ) |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
3,650 |
3,338 |
| PROVISIONS FOR LIABILITIES | 17 | (288 | ) | (148 | ) |
| PENSION ASSET | 20 | 614 | 405 |
| NET ASSETS | 3,976 | 3,595 |
| CAPITAL AND RESERVES |
| Called up share capital | 18 | 79 | 79 |
| Retained earnings | 19 | 3,897 | 3,516 |
| SHAREHOLDERS' FUNDS | 3,976 | 3,595 |
| The financial statements were approved by the Board of Directors and authorised for issue on 14 May 2025 and were signed on its behalf by: |
| Mr R S Brand - Director |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| COMPANY BALANCE SHEET |
| 30 SEPTEMBER 2024 |
| 2024 | 2023 |
| Notes | £'000 | £'000 | £'000 |
| FIXED ASSETS |
| Intangible assets | 9 |
| Tangible assets | 10 |
| Investments | 11 |
| CURRENT ASSETS |
| Stocks | 12 |
| Debtors | 13 |
| Cash at bank |
| CREDITORS |
| Amounts falling due within one year | 14 |
| NET CURRENT LIABILITIES | ( |
) | ( |
) |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
| PROVISIONS FOR LIABILITIES | 17 |
| NET ASSETS |
| CAPITAL AND RESERVES |
| Called up share capital | 18 |
| Retained earnings | 19 |
| SHAREHOLDERS' FUNDS |
| Company's profit for the financial year | 2,625 | 920 |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| CONSOLIDATED STATEMENT OF CHANGES IN EQUITY |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| Called up |
| share | Retained | Total |
| capital | earnings | equity |
| £'000 | £'000 | £'000 |
| Balance at 1 October 2022 | 79 | 2,873 | 2,952 |
| Changes in equity |
| Total comprehensive income | - | 643 | 643 |
| Balance at 30 September 2023 | 79 | 3,516 | 3,595 |
| Changes in equity |
| Total comprehensive income | - | 380 | 380 |
| Balance at 30 September 2024 | 79 | 3,896 | 3,975 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| COMPANY STATEMENT OF CHANGES IN EQUITY |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| Called up |
| share | Retained | Total |
| capital | earnings | equity |
| £'000 | £'000 | £'000 |
| Balance at 1 October 2022 |
| Changes in equity |
| Total comprehensive income | - |
| Balance at 30 September 2023 |
| Changes in equity |
| Total comprehensive income | - |
| Balance at 30 September 2024 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| CONSOLIDATED CASH FLOW STATEMENT |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 2024 | 2023 |
| Notes | £'000 | £'000 |
| Cash flows from operating activities |
| Cash generated from operations | 1 | 568 | 6,699 |
| Interest paid | (12 | ) | (195 | ) |
| Interest element of hire purchase payments paid |
- |
(2 |
) |
| Finance costs paid | (11 | ) | - |
| Tax paid | (209 | ) | (507 | ) |
| Net cash from operating activities | 336 | 5,995 |
| Cash flows from investing activities |
| Purchase of intangible fixed assets | (260 | ) | (335 | ) |
| Purchase of tangible fixed assets | (290 | ) | (91 | ) |
| Sale of intangible fixed assets | - | 8 |
| Consideration - subsidiaries acquisition | (850 | ) | (4,905 | ) |
| Interest received | 33 | 10 |
| Net cash from investing activities | (1,367 | ) | (5,313 | ) |
| Cash flows from financing activities |
| Capital repayments in year | (12 | ) | (24 | ) |
| Net cash from financing activities | (12 | ) | (24 | ) |
| (Decrease)/increase in cash and cash equivalents | (1,043 | ) | 658 |
| Cash and cash equivalents at beginning of year |
2 |
1,813 |
1,155 |
| Cash and cash equivalents at end of year | 2 | 771 | 1,813 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 1. | RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS |
| 2024 | 2023 |
| £'000 | £'000 |
| Profit before taxation | 427 | 589 |
| Depreciation charges | 173 | 291 |
| Loss on disposal of fixed assets | 102 | 2 |
| Amortisation | 1,245 | 1,360 |
| Current service cost | 24 | 37 |
| Pension funding contributions | (112 | ) | (194 | ) |
| Impairment of fixed assets | - | 643 |
| Finance costs | 23 | 197 |
| Finance income | (57 | ) | (28 | ) |
| 1,825 | 2,897 |
| Decrease in stocks | 4 | 13 |
| Decrease/(increase) in trade and other debtors | 489 | (368 | ) |
| (Decrease)/increase in trade and other creditors | (1,750 | ) | 4,157 |
| Cash generated from operations | 568 | 6,699 |
| 2. | CASH AND CASH EQUIVALENTS |
| The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts: |
| Year ended 30 September 2024 |
| 30/9/24 | 1/10/23 |
| £'000 | £'000 |
| Cash and cash equivalents | 771 | 1,813 |
| Year ended 30 September 2023 |
| 30/9/23 | 1/10/22 |
| £'000 | £'000 |
| Cash and cash equivalents | 1,813 | 1,155 |
| 3. | ANALYSIS OF CHANGES IN NET FUNDS |
| At 1/10/23 | Cash flow | At 30/9/24 |
| £'000 | £'000 | £'000 |
| Net cash |
| Cash at bank and in hand | 1,813 | (1,042 | ) | 771 |
| 1,813 | (1,042 | ) | 771 |
| Debt |
| Finance leases | (12 | ) | 12 | - |
| (12 | ) | 12 | - |
| Total | 1,801 | (1,030 | ) | 771 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 1. | COMPANY INFORMATION |
| Partnering Health Limited was incorporated on 11 April 2008 under the Companies Act 2006, as a private limited company and is registered in England and Wales. The principal activity of the group is the provision of services in the healthcare sector. The registered office address is Onyx, 12 Little Park Farm Road, Segensworth Roundabout, West Fareham, Hampshire, PO15 5TD. |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| The presentation currency is £ sterling. |
| Going concern |
| The financial statements have been prepared on the going concern basis. |
| Financial reporting standard 102 - reduced disclosure exemptions |
| The parent company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland": |
| o the requirement of paragraph 3.17(d); |
| o the requirements of Section 7 Statement of Cash Flows; |
| o the requirements of paragraphs 11.42, 11.44, 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c); |
| o the requirements of paragraphs 12.26, 12.27, 12.29(a), 12.29(b) and 12.29A; |
| o the requirements of paragraphs 26.18(b), 26.19 to 26.21 and 26.23; |
| o the requirement of paragraph 33.7. |
| Basis of consolidation |
| The consolidated financial statements incorporate the results of Partnering Health Limited and all of its subsidiary undertakings as at 30 September 2024 using the acquisition method of accounting as required. Where the acquisition method is used, the results of subsidiary undertakings are included from the date of acquisition. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. Subsidiaries are excluded from consolidation from the date that control ceases. |
| Related party exemption |
| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the Group. |
| Transactions between Group entities which have been eliminated on consolidation are not disclosed within the financial statements. |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 2. | ACCOUNTING POLICIES - continued |
| Significant judgements and estimates |
| The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date, and the amounts reported for revenues and expenses during the year. However, the nature of estimation means that actual outcomes could differ from those estimates. |
| The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements. |
| Leases |
| A lease that does not transfer substantially all of the risks and rewards of ownership is classified as an operating lease and is therefore not included in the statement of financial position. |
| Intangibles and goodwill |
| On acquisition, the directors use their judgement to determine the fair value of any intangibles to recognise separately from goodwill. This is based on their knowledge and experience in the sector. |
| Other key sources of estimation uncertainty |
| Useful life of goodwill |
| A reliable estimate is made of the useful life of goodwill arising on acquisitions. The estimate is based on the directors knowledge of the underlying company and sector. |
| Contract accounting |
| Revenue and costs relating to long term contracts are recognised when the service is provided. Any costs in relation to contract set up are deferred where appropriate in line with the revenue recognition. This involves estimating the revenue and costs over the period of the contract. |
| Turnover |
| Turnover represents net sales during the year adjusted for accrued and deferred income where applicable. |
| Turnover relates to the provision of healthcare and recruitment services. Revenue is recognised on the provision of the service. |
| Long-term contracts are assessed on a contract by contract basis and are reflected in the Consolidated Income Statement by recording turnover and related costs as each contract progresses. |
| Intangible fixed assets |
| Goodwill recognised represents the excess of the fair value and directly attributable costs of the purchase consideration over the fair values to the Group's interest in the identifiable net assets, liabilities and contingent liabilities acquired. |
| Goodwill is amortised over its expected useful life of 10 years. Goodwill is assessed for impairment when there are indicators of impairment and any impairment is charged to the Consolidated Income Statement. |
| Software development costs recognised represent the capital expenditure on the development of the Group's projects. Where assets are not available for use at the balance sheet date no amortisation has been provided. All remaining software is amortised over its expected useful life of 5 years. |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 2. | ACCOUNTING POLICIES - continued |
| Tangible fixed assets |
| All tangible fixed assets are initially recognised at cost and subsequently carried at cost less accumulated depreciation and accumulated impairment losses. |
| The cost of tangible fixed assets initially recognised includes its purchase price and any cost that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in a manner intended by management. |
| Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows: |
| Leasehold improvements | - 25% reducing balance |
| Fixtures and fittings | - Four to seven years straight line |
| Computer equipment | - Four to five years straight line |
| Medical equipment | - Five years straight line |
| The assets' residual values and useful lives are reviewed and adjusted, if appropriate, at the end of each reporting period. The effect of any change is accounted for prospectively. |
| Fixed assets are derecognised on disposal or when no future economic benefits are expected. On disposal, the difference between the net disposal proceeds and the carrying amount is recognised in the Consolidated Income Statement. |
| Investments |
| Investments are initially recognised at cost and subsequently carried at cost less accumulated impairment losses. |
| Stocks |
| Stocks are valued at the lower of cost and net realisable value. Stocks are valued at purchase price using a first in, first out method. |
| Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation, and where appropriate, the cost of conversion from their existing state to a finished condition. Provision is made where necessary for obsolescent, slow moving and defective stock. |
| Financial instruments |
| The Group only has financial assets and liabilities of the kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and debt instruments are subsequently measured at amortised cost. |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 2. | ACCOUNTING POLICIES - continued |
| Research and development |
| Expenditure on research is written off in the year in which it is incurred. Expenditure on the development of software is capitalised once the following has been demonstrated: |
| - | The technical feasibility of completing the intangible asset so that it will be available for use or sale; |
| - | The intention to complete the intangible asset and use or sell it; |
| - | The ability to use or sell the intangible asset; |
| - | How the intangible asset will generate probable future economic benefits; |
| - | The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and |
| - | The ability to measure reliably the expenditure attributable to the intangible asset during its development. |
| Hire purchase and leasing commitments |
| Where assets are financed by leasing agreements that give rights approximating to ownership (finance leases), the assets are treated as if they had been purchased outright. The amount capitalised is the present value of the minimum lease payments payable over the term of the lease. The corresponding leasing commitments are shown as amounts payable to the lessor. Depreciation on the relevant assets is charged to the Consolidated Income Statement over the estimated useful economic life of the asset. |
| Lease payments are analysed between capital and interest components so that the interest element of the payment is charged to the Consolidated Income Statement over the period of the lease and is calculated so that it represents a constant proportion of the balance of capital repayments outstanding. The capital part reduces the amounts payable to the lessor. |
| All other leases are treated as operating leases. Their annual rentals are charged to the Consolidated Income Statement on a straight line basis over the term of the lease. |
| Pension costs and other post-retirement benefits |
| The Group accounts for its defined benefit pension scheme in accordance with FRS 102. The pension scheme assets are measured using the projected units method. The pension scheme asset is recognised in full and disclosed on the face of the balance sheet. The movement in the scheme asset is split between operating profit and finance costs in the Consolidated Income Statement and the Consolidated Statement of Other Comprehensive Income. |
| In addition, the group makes contributions to a defined contribution scheme, the assets of which are held separately from those of the group in an independently administered fund. Contributions to this scheme are charged to the Consolidated Income Statement as they become payable. |
| 3. | TURNOVER |
| The turnover and profit before taxation are attributable to the principal activities of the group. |
| An analysis of turnover by class of business is given below: |
| 2024 | 2023 |
| £'000 | £'000 |
| Healthcare services | 31,675 | 42,206 |
| Recruitment services | - | 164 |
| 31,675 | 42,370 |
| All turnover arose in the United Kingdom. |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 4. | EMPLOYEES AND DIRECTORS |
| 2024 | 2023 |
| £'000 | £'000 |
| Wages and salaries | 13,029 | 12,245 |
| Social security costs | 1,328 | 1,251 |
| Other pension costs | 317 | 357 |
| 14,674 | 13,853 |
| The average number of employees during the year was as follows: |
| 2024 | 2023 |
| Clinical | 244 | 191 |
| Non-clinical | 198 | 260 |
| 2024 | 2023 |
| £ | £ |
| Directors' remuneration | 653,477 | 609,097 |
| Directors' pension contributions to money purchase schemes | 5,283 | 6,604 |
| Compensation to director for loss of office | - | 87,836 |
| The number of directors to whom retirement benefits were accruing was as follows: |
| Money purchase schemes | 4 | 5 |
| Information regarding the highest paid director is as follows: |
| 2024 | 2023 |
| £ | £ |
| Emoluments etc | 160,815 | 122,835 |
| Pension contributions to money purchase schemes | 1,321 | 1,320 |
| 5. | OPERATING PROFIT |
| The operating profit is stated after charging: |
| 2024 | 2023 |
| £'000 | £'000 |
| Hire of plant and machinery | 10 | 20 |
| Depreciation - owned assets | 168 | 278 |
| Depreciation - assets on hire purchase contracts | 5 | 12 |
| Loss on disposal of fixed assets | 102 | 2 |
| Goodwill amortisation | 1,191 | 1,200 |
| Software development costs amortisation | 55 | 159 |
| Auditors remuneration | 16 | 16 |
| Operating leases | 239 | 208 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 6. | INTEREST PAYABLE AND SIMILAR EXPENSES |
| 2024 | 2023 |
| £'000 | £'000 |
| Interest payable | 23 | 12 |
| Loan interest | - | 183 |
| Hire purchase and finance lease charges | - | 2 |
| 23 | 197 |
| 7. | TAXATION |
| Analysis of the tax charge/(credit) |
| The tax charge/(credit) on the profit for the year was as follows: |
| 2024 | 2023 |
| £'000 | £'000 |
| Current tax: |
| UK corporation tax | - | 88 |
| Over/under provision in prior |
| year | 4 | (30 | ) |
| Total current tax | 4 | 58 |
| Deferred tax | 88 | (193 | ) |
| Tax on profit | 92 | (135 | ) |
| Reconciliation of total tax charge/(credit) included in profit and loss |
| The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below: |
| 2024 | 2023 |
| £'000 | £'000 |
| Profit before tax | 427 | 589 |
| Profit multiplied by the standard rate of corporation tax in the UK of 25 % (2023 - 22.010 %) |
107 |
130 |
| Effects of: |
| Expenses not deductible for tax purposes | 335 | 270 |
| Income not taxable for tax purposes | - | (4 | ) |
| Adjustments to tax charge in respect of previous periods | 4 | (30 | ) |
| Deferred tax previously unprovided | - | (18 | ) |
| Movement in deferred tax unprovided | 1 | 20 |
| Group relief | (381 | ) | (440 | ) |
| Pension payments | (28 | ) | (43 | ) |
| Difference in tax rate | - | (20 | ) |
| Losses eliminated | 54 | - |
| Total tax charge/(credit) | 92 | (135 | ) |
| Tax effects relating to effects of other comprehensive income |
| 2024 |
| Gross | Tax | Net |
| £'000 | £'000 | £'000 |
| Actuarial gains/(losses) | 97 | (52 | ) | 45 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 7. | TAXATION - continued |
| 2023 |
| Gross | Tax | Net |
| £'000 | £'000 | £'000 |
| Actuarial gains/(losses) | (49 | ) | (32 | ) | (81 | ) |
| 8. | INDIVIDUAL INCOME STATEMENT |
| As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements. |
| 9. | INTANGIBLE FIXED ASSETS |
| Group |
| Software |
| development |
| Goodwill | costs | Totals |
| £'000 | £'000 | £'000 |
| COST |
| At 1 October 2023 | 11,465 | 865 | 12,330 |
| Additions | 80 | 260 | 340 |
| At 30 September 2024 | 11,545 | 1,125 | 12,670 |
| AMORTISATION |
| At 1 October 2023 | 1,721 | 663 | 2,384 |
| Amortisation for year | 1,191 | 55 | 1,246 |
| At 30 September 2024 | 2,912 | 718 | 3,630 |
| NET BOOK VALUE |
| At 30 September 2024 | 8,633 | 407 | 9,040 |
| At 30 September 2023 | 9,744 | 202 | 9,946 |
| Company |
| Software |
| development |
| Goodwill | costs | Totals |
| £'000 | £'000 | £'000 |
| COST |
| At 1 October 2023 |
| Additions |
| At 30 September 2024 |
| AMORTISATION |
| At 1 October 2023 |
| Amortisation for year |
| At 30 September 2024 |
| NET BOOK VALUE |
| At 30 September 2024 |
| At 30 September 2023 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 10. | TANGIBLE FIXED ASSETS |
| Group |
| Fixtures |
| Leasehold | and | Medical | Computer |
| improvements | fittings | equipment | equipment | Totals |
| £'000 | £'000 | £'000 | £'000 | £'000 |
| COST |
| At 1 October 2023 | 14 | 646 | 41 | 844 | 1,545 |
| Additions | 5 | 250 | 2 | 33 | 290 |
| Disposals | - | (225 | ) | - | - | (225 | ) |
| At 30 September 2024 | 19 | 671 | 43 | 877 | 1,610 |
| DEPRECIATION |
| At 1 October 2023 | 6 | 395 | 30 | 722 | 1,153 |
| Charge for year | 3 | 96 | 7 | 67 | 173 |
| Eliminated on disposal | - | (123 | ) | - | - | (123 | ) |
| At 30 September 2024 | 9 | 368 | 37 | 789 | 1,203 |
| NET BOOK VALUE |
| At 30 September 2024 | 10 | 303 | 6 | 88 | 407 |
| At 30 September 2023 | 8 | 251 | 11 | 122 | 392 |
| The net book value of tangible fixed assets includes £Nil (2023: £6k) in respect of assets held under hire purchase contracts. |
| Company |
| Fixtures |
| and | Medical | Computer |
| fittings | equipment | equipment | Totals |
| £'000 | £'000 | £'000 | £'000 |
| COST |
| At 1 October 2023 |
| Additions |
| Disposals | ( |
) | ( |
) |
| At 30 September 2024 |
| DEPRECIATION |
| At 1 October 2023 |
| Charge for year |
| Eliminated on disposal | ( |
) | ( |
) |
| At 30 September 2024 |
| NET BOOK VALUE |
| At 30 September 2024 |
| At 30 September 2023 |
| The net book value of tangible fixed assets includes £NIL (2023: £6k) in respect of assets held under hire purchase contracts. |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 11. | FIXED ASSET INVESTMENTS |
| Company |
| Shares in |
| group |
| undertakings |
| £'000 |
| COST |
| At 1 October 2023 |
| Additions |
| At 30 September 2024 |
| NET BOOK VALUE |
| At 30 September 2024 |
| At 30 September 2023 |
| The group or the company's investments at the Balance Sheet date in the share capital of companies include the following: |
| Subsidiaries |
| Registered office: Onyx, 12 Little Park Farm Road, Segensworth Roundabout, West Fareham, Hampshire, PO15 5TD |
| Nature of business: |
| % |
| Class of shares: | holding |
| Registered office: Onyx, 12 Little Park Farm Road, Segensworth Roundabout, West Fareham, Hampshire, PO15 5TD |
| Nature of business: |
| % |
| Class of shares: | holding |
| Registered office: F5, Buchan House Carnegie Campus, Enterprise Way, Dunfermline, Fife, Scotland, KY11 8PL |
| Nature of business: |
| % |
| Class of shares: | holding |
| Registered office: Onyx, 12 Little Park Farm Road, Segensworth Roundabout, West Fareham, Hampshire, PO15 5TD |
| Nature of business: |
| % |
| Class of shares: | holding |
| Registered office: Onyx, 12 Little Park Farm Road, Segensworth Roundabout, West Fareham, Hampshire, PO15 5TD |
| Nature of business: |
| % |
| Class of shares: | holding |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 12. | STOCKS |
| Group | Company |
| 2024 | 2023 | 2024 | 2023 |
| £'000 | £'000 | £'000 | £'000 |
| Stocks | 106 | 110 |
| 13. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| Group | Company |
| 2024 | 2023 | 2024 | 2023 |
| £'000 | £'000 | £'000 | £'000 |
| Trade debtors | 3,101 | 2,740 |
| Amounts owed by group undertakings | 2,059 | 2,698 |
| Other debtors | 12 | 17 |
| Corporation tax | 312 | 107 |
| Prepayments and accrued income | 771 | 976 |
| 6,255 | 6,538 |
| 14. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| Group | Company |
| 2024 | 2023 | 2024 | 2023 |
| £'000 | £'000 | £'000 | £'000 |
| Hire purchase contracts (see note 15) | - | 12 |
| Trade creditors | 1,039 | 1,229 |
| Amounts owed to group undertakings | 7,692 | 6,121 |
| Social security and other taxes | 419 | 417 |
| VAT | 1 | 2 | 1 | 2 |
| Other creditors | 42 | 132 |
| Accruals and deferred income | 3,736 | 7,548 |
| 12,929 | 15,461 |
| 15. | LEASING AGREEMENTS |
| Minimum lease payments fall due as follows: |
| Group |
| Hire purchase contracts |
| 2024 | 2023 |
| £'000 | £'000 |
| Net obligations repayable: |
| Within one year | - | 12 |
| Company |
| Hire purchase contracts |
| 2024 | 2023 |
| £'000 | £'000 |
| Net obligations repayable: |
| Within one year |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 15. | LEASING AGREEMENTS - continued |
| Group |
| Non-cancellable |
| operating leases |
| 2024 | 2023 |
| £'000 | £'000 |
| Within one year | 286 | 239 |
| Between one and five years | 403 | 412 |
| 689 | 651 |
| Company |
| Non-cancellable |
| operating leases |
| 2024 | 2023 |
| £'000 | £'000 |
| Within one year |
| Between one and five years |
| 16. | SECURED DEBTS |
| The following secured debts are included within creditors: |
| Group |
| 2024 | 2023 |
| £'000 | £'000 |
| Hire purchase contracts | - | 12 |
| Security over hire purchase contracts has been given by way of a fixed and floating charge over the assets financed. |
| 17. | PROVISIONS FOR LIABILITIES |
| Group | Company |
| 2024 | 2023 | 2024 | 2023 |
| £'000 | £'000 | £'000 | £'000 |
| Deferred tax | 288 | 148 | 65 | 88 |
| Group |
| Deferred tax |
| £'000 |
| Balance at 1 October 2023 | 148 |
| Charge to Income Statement during year | 88 |
| Charge to OCI | 52 |
| Balance at 30 September 2024 | 288 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 17. | PROVISIONS FOR LIABILITIES - continued |
| Company |
| Deferred tax |
| £'000 |
| Balance at 1 October 2023 |
| Credit to Income Statement during year | ( |
) |
| Balance at 30 September 2024 |
| Group |
| 2024 | 2023 |
| The deferred tax liability comprises: | £'000 | £'000 |
| Deferred tax liability on pension asset | 154 | 101 |
| Deferred tax liability on accelerated capital allowances | 141 | 116 |
| Deferred tax asset on tax losses carried forward | - | (54 | ) |
| Deferred tax asset on other timing differences | (7 | ) | (15 | ) |
| 288 | 148 |
| Company |
| 2024 | 2023 |
| The deferred tax liability comprises: | £'000 | £'000 |
| Deferred tax liability on accelerated capital allowances | 72 | 103 |
| Deferred tax asset on other timing differences | (7 | ) | (15 | ) |
| 66 | 88 |
| 18. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2024 | 2023 |
| value: | £'000 | £'000 |
| Ordinary | £0.01 | 79 | 79 |
| The ordinary shares have attached to them full voting, dividend rights and rights on winding up. |
| 19. | RESERVES |
| Group |
| Retained |
| earnings |
| £'000 |
| At 1 October 2023 | 3,517 |
| Profit for the year | 335 |
| Other comprehensive income | 45 |
| At 30 September 2024 | 3,897 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 19. | RESERVES - continued |
| Company |
| Retained |
| earnings |
| £'000 |
| At 1 October 2023 |
| Profit for the year |
| At 30 September 2024 |
| Retained earnings represent accumulated profit and losses to date. |
| 20. | EMPLOYEE BENEFIT OBLIGATIONS |
| The Group are party to a funded defined benefit scheme providing benefits to the members based on final pensionable pay. The scheme commenced on 15 April 2015. |
| Contributions to the scheme are charged to the Consolidated Income Statement so as to spread the cost of pensions evenly over employees' working lives with the Group. |
| The assets of the scheme are held separately from those of the Group, being invested in managed funds. |
| Employer contributions amounting to £112k (2023: £194k) were paid during the year. |
| The last full actuarial valuation was carried out at 31 December 2021 and updated to 30 September 2024 by a qualified independent actuary on an FRS 102 basis. |
| The amounts recognised in the balance sheet are as follows: |
| Defined benefit |
| pension plans |
| 2024 | 2023 |
| £'000 | £'000 |
| Present value of funded obligations | (753 | ) | (727 | ) |
| Fair value of plan assets | 1,367 | 1,132 |
| 614 | 405 |
| Present value of unfunded obligations | - | - |
| Surplus | 614 | 405 |
| Net asset | 614 | 405 |
| The amounts recognised in profit or loss are as follows: |
| Defined benefit |
| pension plans |
| 2024 | 2023 |
| £'000 | £'000 |
| Current service cost | 24 | 37 |
| Net interest from net defined benefit asset/liability |
(24 |
) |
(18 |
) |
| Past service cost | - | - |
| - | 19 |
| Actual return on plan assets | 128 | (2 | ) |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 20. | EMPLOYEE BENEFIT OBLIGATIONS - continued |
| Changes in the present value of the defined benefit obligation are as follows: |
| Defined benefit |
| pension plans |
| 2024 | 2023 |
| £'000 | £'000 |
| Opening defined benefit obligation | 727 | 684 |
| Current service cost | 24 | 37 |
| Contributions by scheme participants | 11 | 10 |
| Interest cost | 39 | 36 |
| Actuarial losses/(gains) | (32 | ) | (7 | ) |
| Benefits paid | (16 | ) | (33 | ) |
| 753 | 727 |
| Changes in the fair value of scheme assets are as follows: |
| Defined benefit |
| pension plans |
| 2024 | 2023 |
| £'000 | £'000 |
| Opening fair value of scheme assets | 1,132 | 963 |
| Contributions by employer | 112 | 194 |
| Contributions by scheme participants | 11 | 10 |
| Interest income | 63 | 54 |
| Actuarial gains/(losses) | 65 | (56 | ) |
| Benefits paid | (16 | ) | (33 | ) |
| 1,367 | 1,132 |
| The amounts recognised in other comprehensive income are as follows: |
| Defined benefit |
| pension plans |
| 2024 | 2023 |
| £'000 | £'000 |
| Actuarial gains/(losses) | 97 | (49 | ) |
| 97 | (49 | ) |
| The major categories of scheme assets as amounts of total scheme assets are as follows: |
| Defined benefit |
| pension plans |
| 2024 | 2023 |
| £'000 | £'000 |
| Equities | - | 387 |
| Bonds | 1,367 | 594 |
| Multi-Asset | - | 151 |
| 1,367 | 1,132 |
| PARTNERING HEALTH LIMITED (REGISTERED NUMBER: 06563486) |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 30 SEPTEMBER 2024 |
| 20. | EMPLOYEE BENEFIT OBLIGATIONS - continued |
| Principal actuarial assumptions at the balance sheet date (expressed as weighted averages): |
| 2024 | 2023 |
| Discount rate | 5.00% | 5.35% |
| Rate of pensionable salary increases | 3.10% | 3.10% |
| RPI for revaluation deferment | 3.40% | 3.55% |
| RPI for increase in payment | 3.00% | 3.20% |
| CPI for revaluation deferment | 2.70% | 2.85% |
| CPI for increase in payment | 2.75% | 2.90% |
| 21. | CONTINGENT LIABILITIES |
| The group has a cross guarantee with its group company, PHL Group Midco Limited, in favour of MNL Nominees Limited to guarantee its loan notes. The total indebtedness at the balance sheet date is £8,128k (2023: £7,509k). |
| The group has a cross guarantee with its group company, PHL Group Midco Limited, in favour of Dr Timothy Wright to guarantee his loan notes. The total indebtedness at the balance sheet date is £912k (2023: £Nil). |
| The group has a cross guarantee with its group company, PHL Group Midco Limited, in favour of Clive Boothby, Kenneth Patrick and Elizabeth Preston to guarantee their loan notes. The total indebtedness at the balance sheet date is £4,614k (2023: £Nil). |
| The group has a cross guarantee with its group company, PHL Group Finance Limited, in favour of TC Loans Limited to guarantee its loan. The total indebtedness at the balance sheet date is £13,000k (2023: £13,000k). |
| 22. | RELATED PARTY DISCLOSURES |
| During the year purchases of £15k (2023: £34k) were made from Orchard Health Consultancy Limited, a company in which Dr T S Wright is a shareholder. The balance due to Orchard Health Consultancy Limited at the year end was £Nil (2023: £Nil). |
| During the year purchases of £11k (2023: £183k) were made from Zeyez Ltd, a company in which a director of Salveas Limited is also a shareholder and director. The balance due to Zeyez Ltd at the year end was £Nil (2023: £Nil). |
| During the year purchases of £Nil (2023: £1k) were made from Clinical Vantage Limited, a company in which Gemma Bond is a shareholder and director. The balance due to Clinical Vantage Limited at the year end was £Nil (2023: £Nil). |
| During the year sales of £82k (2023: £Nil) were made to Blossom Health, an entity in which Ross Brand is a partner. The balance due from Blossom Health at year end was £15k (2023: £Nil). |
| During the year, a total of key management personnel compensation of £830k (2023: £900k) was paid. |
| 23. | POST BALANCE SHEET EVENTS |
| Post year end the company declared a dividend of £6,189,875. |
| 24. | ULTIMATE CONTROLLING PARTY |
| The immediate parent company is Partnering Health Holdings Limited, a company registered in England & Wales. The ultimate parent company is PHL Group Holdco Limited, a company registered in England & Wales. |
| The smallest and largest group in which the results of the group are consolidated is that headed by PHL Group Holdco Limited. The accounts are available to the public and may be obtained from the Registrar of Companies. |
| The directors do not consider there to be an ultimate controlling party. |